Oramed Receives Patent in the European Union for the Oral Delivery of Insulin

Oramed Receives Patent in the European Union for the Oral Delivery of Insulin

PR Newswire

JERUSALEM, Nov. 19, 2013

JERUSALEM, Nov. 19, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
(NASDAQCM: ORMP) (www.oramed.com), a developer of oral drug delivery systems,
announced today that the European Patent Office has allowed the Company's
patent for its invention, titled "Methods and Compositions for Oral
Administrations of Proteins."

Europe is one of the world's largest healthcare markets with an estimated $322
billion market value in 2012, accounting for over one quarter of the world
pharmaceutical market, according to a report by the European Federation of
Pharmaceutical Industries and Associations. According to Frost & Sullivan the
European diabetes market accounted for $8.6 billion in revenues in 2010 and is
estimated to grow to $14 billion by 2017, driven by new classes of drugs to
treat the disease.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's Protein Oral Delivery (POD™) technology is based
on over 30 years of research by top research scientists at Jerusalem's
Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of
diabetes through its proprietary flagship product, an orally ingestible
insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients
with type 2 diabetes (T2DM) under an Investigational New Drug application with
the U.S. Food and Drug Administration, and with its oral exenatide capsule
(ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and
T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical
trials of ORMD-0801 for the treatment of type 1 diabetes. The company's
corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss our clinical trials or revolutionizing the treatment of diabetes with
our products. These forward-looking statements and their implications are
based on the current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent protection
for our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional funding required
to conduct our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements:
changes in technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to timely
develop and introduce new technologies, products and applications; lack of
validation of our technology as we progress further and lack of acceptance of
our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our process; greater
cost of final product than anticipated; loss of market share and pressure on
pricing resulting from competition; laboratory results that do not translate
to equally good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could cause the
actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Oramed undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office: +972-2-566-0001
Tel US:1-718-831-2512
Mobile: +972-54-792-4438
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Website: http://www.oramed.com
 
Press spacebar to pause and continue. Press esc to stop.